At time of ARVD diagnosis, 71.8% of patients had evidence of extra-renal atherosclerosis, 50.0% were receiving an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) 37.1% a beta blocker, 54.5% aspirin and 55.9% a statin (Table 1). Here, ACE is linked to renal artery atheroma.